Investigational drug · Phase 2
PN20
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Thrombocytopenia Associated With Chronic Liver Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
4
Any phase or sponsor naming "PN20"
First trial start
2025
Jun 6, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PN20", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thrombocytopenia Associated With Chronic Liver Disease
Approved drugs for the same conditions: Hematology and blood cancers · Cardiovascular and metabolic · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "PN20" as an intervention, largest first.
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT07446491 · 54 participants · Start Jun 6, 2025 · Primary completion Oct 10, 2026
Drug: PN20; Placebo · For: Thrombocytopenia Associated With Chronic Liver Disease
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 8 sites in all
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT06523088 · 27 participants · Start Jun 16, 2022 · Primary completion Jan 5, 2023
Drug: PN20; Placebo · For: Chemotherapy-induced Thrombocytopenia; Immune Thrombocytopenic Purpura
Sites: Suzhou, China
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT06521931 · 24 participants · Start Dec 6, 2023 · Primary completion Jan 13, 2025
Drug: PN20 · For: Thrombocytopenia
Sites: Baoding, China; Luoyang, China; Zhengzhou, China · 6 sites in all
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT06880081 · 12 participants · Start Mar 7, 2025 · Primary completion Feb 14, 2026
Drug: PN20 treatment · For: Primary Immune Thrombocytopenia (ITP)
Sites: Guiyang, China; Nanchang, China; Jining, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Bone-Targeted Nanosystems Induce Multiple Types of Cell Death and Suppress Osteoclasts via Sonodynamic Sensitization Therapy to Treat Bone Metastatic Tumors.
Lei Q, Yang Z, Zhu G, et al. · Small 2026
- Long-lasting remodeling of astrocytes in an Scna1+/- mouse model of Dravet syndrome.
Genin A, Janvier A, Moujellil-Legagneur T, et al. · Epilepsia 2026
- Maternal antibiotic exposure-mediated alterations in basal, and allergen-induced lung function are associated with altered recruitment of eosinophils to the developing lung.
Wilburn AN, Korkmaz RÜ, McAlees JW, et al. · Front Immunol 2025
- STAT3-controlled CHI3L1/SPP1 positive feedback loop demonstrates the spatial heterogeneity and immune characteristics of glioblastoma.
Yu W, Gui S, Peng L, et al. · Dev Cell 2025
- The impact of cooling and Moringa supplementation on oxidative stress in serum and milk, including milk cytokines, in heat stressed lactating sows and their litters.
Ogundare WO, Beckett LM, Reis LG, et al. · Transl Anim Sci 2025
- The pathophysiological impact of intra-abdominal hypertension in pigs.
Wise R, Rodseth R, Párraga-Ros E, et al. · PLoS One 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.